中国临床药理学杂志2024，Vol.40Issue(17)：2591-2595,5.DOI:10.13699/j.cnki.1001-6821.2024.17.028
阿替利珠单抗联合贝伐珠单抗、化疗治疗晚期非小细胞肺癌的研究现状
Research status of atezolizumab combined with bevacizumab plus chemotherapy for the treatment of advanced non-small cell lung cancer
摘要
Abstract
Immunotherapy had completely changed the treatment for patients with advanced non-small cell lung cancer.However,due to its low response rate as a monotherapy,many patients had not been able to benefit from the treatment.The combination of immunotherapy with anti-angiogenic drugs and chemotherapy might have helped to address this issue,and the regimen of atezolizumab with bevacizumab,carboplatin,and paclitaxel(ABCP)had been approved as a first-line treatment for advanced metastatic non-small cell lung cancer,holding great potential for application.This review had summarized the antitumor mechanisms of the ABCP regimen,had concluded the current status of its clinical application for different subgroups and treatment sequences,the safety and cost-effectiveness of the regimen,as well as the possibilities for alternative drug choices within the ABCP regimen and the development of new drugs,providing a reference for the personalized application of the ABCP regimen in patients with non-small cell lung cancer.关键词
抗血管生成药/非小细胞肺癌/免疫治疗/联合治疗Key words
anti-angiogenic drug/non-small cell lung cancer/immunotherapy/combination therapy分类
医药卫生引用本文复制引用
赖厚芸,梁燕,李凤,周进,陈燕,王怡鑫..阿替利珠单抗联合贝伐珠单抗、化疗治疗晚期非小细胞肺癌的研究现状[J].中国临床药理学杂志,2024,40(17):2591-2595,5.基金项目
中国药学会医院药学专业委员会科研专项基金资助项目(CPA-Z05-ZC-2022-002) （CPA-Z05-ZC-2022-002）
四川省个体化药物治疗重点实验室基金资助项目(2021YB03) （2021YB03）
四川省肿瘤医院青年优秀基金资助项目(YB2023026) （YB2023026）
